1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Biosimilars in 2014: An Interview With FDA New Drugs Head John Jenkins

 
• By Ramsey Baghdadi

In addition to John Jenkins’ role as FDA’s top new drug review manager, he serves as head of the Biosimilars Review Committee—the internal panel tasked with grappling with actual application review issues for the abbreviated 351(k) program. The RPM Report spoke with Jenkins during the FDA/CMS Summit for Biopharmaceutical Executives in December. Here is an edited transcript of the conversation.

The RPM Report: Has the agency received any biosimilar applications yet under the 351(k) pathway?

John Jenkins: The answer I’m supposed to give is that we haven’t approved any applications under the 351(k) biosimilar pathway....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Senate Bill Would Boost Oversight Of US FDA User Fee Program Following Trump Reorganization

 
• By Sarah Karlin-Smith

Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 
• By Francesca Bruce

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines Agency 30th anniversary.

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By Sue Sutter

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.